Intellia Dismisses Four Counterclaims in BlueAllele Patent Suit

Intellia Therapeutics Inc. dropped four of its remaining counterclaims, including a bid to correct the asserted patents’ inventorship, in BlueAllele Corp.'s infringement suit over gene-editing technology.

Intellia also dropped its claim for tortious interference with prospective business opportunities and claims for unfair or deceptive trade practices claims under both Massachusetts and Minnesota state laws. Judge John F. Murphy of the US District Court for the District of Delaware granted the stipulation and dismissed those counterclaims with prejudice Tuesday.

Murphy in February 2025 granted BlueAllele’s request to dismiss Intellia’s counterclaim for unjust enrichment because such disputes are governed by federal patent ...